Vaccine

Renalogic Receives Second Consecutive Savings Certification From the Validation Institute for Dialysis Claims Repricing

Self-funded plans save 84.5% compared with their ‘Allowed Amount' when using Renalogic's ImpactProtect service.CHICAGO, IL / ACCESSWIRE / November 2,…

2 years ago

Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates

Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to…

2 years ago

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves…

2 years ago

DHSS launches interactive statewide flu dashboard

Flu season officially started October 1JEFFERSON CITY, Mo., Oct. 13, 2023 (GLOBE NEWSWIRE) -- The Missouri Department of Health and…

2 years ago

Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023

CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live…

2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD – The Liver Meeting® 2023

Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation…

2 years ago

Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new…

2 years ago

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,…

2 years ago

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301).Decrease…

2 years ago